Epidiolex, a prescription medicine containing a standardized formulation of plant-derived cannabidiol (CBD), has been reclassified today by the US Drug Enforcement Administration to Schedule V — the lowest restriction classification available under federal law. The rescheduling change is only specific to Epidiolex, and does not amend the schedule I status of either whole-plant cannabis of CBD.